Panitumumab biosimilar - PanPharmaceuticals USA
Latest Information Update: 17 Jun 2015
At a glance
- Originator PanPharmaceuticals USA
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 17 Jun 2015 Discontinued for Colorectal cancer in USA (unspecified route)
- 17 Jun 2015 PanPharmaceuticals USA has ceased its operations